The validity of carbohydrate antigen 19-9 in serum and saliva as a new type for diagnosis in Iraqi kids having cystic fibrosis

• Published in: International journal of research in pharmaceutical sciences Vol. 10; no. 2; pp. 1440 - 1443
• Main Authors: Maryam Qussay Issa, Shatha MJ AL-Khateeb, Hala Sameh Arif, Muhi Kadhem AL-Janabi
• Format: Journal Article
• Language: English
• Published: 29.04.2019
• ISSN: 0975-7538; 0975-7538
• DOI: 10.26452/ijrps.v10i2.713

Cystic fibrosis is a life-limiting, recessive disease; it occurs due to mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Carbohydrate antigen 19-9 (CA19.9) is a tumour-associated, primarily occur in patients having biliary tract and pancreatic cancers but are also observed in patients having other malignancies. Conditions related to benign like cholestasis, cirrhosis, cholangitis, plus pancreatitis also result in CA 19-9 elevations. Raised levels of serum CA 19-9 seems in CF patient to be related to disease pulmonary exacerbation also in the lung the amount of sputum. Investigate whether serum and saliva (CA19.9) level may contribute to cystic fibrosis diagnosis establishment in patients. This "case-control study" consists of 80 individuals (30 patients and 50 healthy controls). Their age was range between one month and 18 years. Blood and saliva samples were taken from patients. Saliva level in patients was 1.775±1.030U/ml (P<0.001) as compared to control group (0.956±0.682 U/ml). A serum level of CA19.9 was found to be increased (P<0.001) by 0.818±0.601 U/ml in CF patients as compared to healthy (0.334±0.101 U/ml) control. From this study, we can conclude that the salivary CA19.9 level can be diagnosed as a marker for cystic fibrosis.